Mirabegron/Solifenacin Succinate

米拉贝隆/琥珀酸索利那新

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameMirabegron/Solifenacin Succinate
Drug Alias NameMirabegron/Solifenacin Succinate索利那新/米拉贝隆Solifenacin Succinate+Mirabegron米拉贝隆/索利那新Solifenacin Succinate•Mirabegron +[15] 
ClassificationSmall molecules
Mechanisms of ActionBeta-3 adrenergic receptor agonistsMuscarinic acetylcholine receptor M3 antagonists
TargetsBeta-3 adrenergic receptorMuscarinic acetylcholine receptor M3
Therapy Area/IndicationsUrinary Bladder, Overactive
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[46] 
CombinationsYes MirabegronSolifenacin Succinate
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAstellas Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesGenuine Research Center, EgyptAstellas Pharma Technologies IncAstellas Pharma Europe Bv +[4] 
Inactive CompaniesN/A
Active IndicationsUrinary Bladder, Overactive
Inactive IndicationsN/A

Other Information

ATC CodeG04BD
Related LinksN/A